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C-reactive protein (CRP) is a blood component comprised of ﬁve identical subunits with a combined
molecular mass of 110kDa; in the presence of Ca
þþ it binds phosphocholine (PC) with high afﬁnity.
Ligand-bound CRP activates complement and the protein reportedly binds various Fc receptors.
Coincident with a now decade-long resurgence in clinical interest in associations of CRP with disease,
our laboratory has been investigating the biology of CRP in vivo using human CRP transgenic mice
(CRPtg). At that time we conﬁrmed that CRP affects a host defense function mediated at least in part
through the elimination of pathogens. Less appreciated and not as well understood as CRP’s ability to
bind antigen and aid in the elimination of microbes, is its known ability to bind autoantigens and
presumed capacity to promote clearance of apoptotic cells. These latter properties of CRP have long
been suspected to contribute to homeostasis and to autoimmune disease. In this article we review and
update the evidence generated in CRPtg by our group and invitro by others’ that indicates CRP is more
than just an antimicrobial molecule and convenient marker of inﬂammation—rather, it protects against
autoimmunity. A mechanistic hypothesis is presented to account for this cause-and-effect relationship.
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WHAT IS CRP?
C-reactive protein (CRP) is one of only two acute phase
proteins known as “pentraxins” (Osmand et al., 1977;
Gerwurz et al., 1995). They share extensive sequence and
structural homology (Emsley et al., 1994; Gerwurz et al.,
1995; Shrive et al., 1996) and are differentiated based on
function; those that bind best to phosphocholine (PC) are
CRP-like (Volanakis and Kaplan, 1971; Anderson et al.,
1978) while those that bind best to phosphoethanolamine
(PE) are serum amyloid P-component (SAP)-like (Hind
et al., 1985; Schwalbe et al., 1992). Most animals make
both but usually only one is an acute phase reactant
(Kushner and Mackiewicz, 1993), thus in humans within
hours after an inﬂammatory insult, blood CRP level rises
dramatically but SAP does not (Kushner, 1982; Pepys and
Baltz, 1983; Kushner and Mackiewicz, 1993), whereas in
mice SAP increases with kinetics and magnitude like CRP
in humans (Pepys et al., 1979). Unique among mammals,
mouse CRP is always a trace blood component (Bodmer
and Siboo, 1977; Whitehead et al., 1990).
Because of its predictable acute phase behavior in
humans, measurement of blood CRP has proven clinical
utility, and extensive data has been collected showing
signiﬁcant statistical association between CRP level and
likelihood and severity of various inﬂammatory diseases,
including autoimmunity (Young et al., 1991; Morrow and
Ridker, 2000). Here we review and update evidence
generated by our group and others’ that indicates CRP is
more than just a convenient marker of inﬂammation—
rather, the association of CRP with autoimmune disease
arises from underlying biology, i.e. cause-and-effect
relationships. A hypothesis is then proffered to account for
these relationships.
WHAT DOES CRP DO AND HOW DOES IT DO IT?
The ﬁrst activity ascribed to CRP was its ability to
precipitate the Streptococcus pneumoniae cell wall
teichoic acid, C-polysaccharide (Abernathy and Avery,
1941). The reaction depends on the protein’s Ca
þþ
dependent binding to PC (Volanakis and Kaplan, 1971),
a major constituent of at least two cell wall antigens
common to all serotypes of pneumococci; teichoic acid
and lipoteichoic acid (Tomasz, 1967; Fischer, 2000). PC
was thus the ﬁrst CRP ligand discovered and so far is the
best characterized. Unfortunately, the fact that CRP binds
to ligands other than PC is often overlooked. Among the
lesser appreciated CRP ligands are a variety of
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nuclear ribonucleoprotein, nuclear envelope protein, and
apoptotic cells (Robey et al., 1985; Du Clos et al., 1988;
Du Clos, 1989; Minota et al., 1993; Gershov et al., 2000;
Lee et al., 2002). Binding to most of these ligands requires
Ca
þþ and can be inhibited by PC, indicating that a single
promiscuous ligand-binding site on CRP accommodates
diverse structural groups. Details about the architecture of
the ligand-binding site emerged from protein mutagenesis
studies (Agrawal et al., 1992; 1997) and solution of the
crystal structure of native CRP (Shrive et al., 1996). CRP
per se consists of ﬁve non-covalently associated subunits
of 206 amino acids arranged in cyclic symmetry. Each
subunit has one PC-binding site, and all ﬁve binding sites
are oriented towards the same face of the pentamer. As a
result, CRP can associate with high avidity to surfaces that
display appropriate ligands in an array, such as on the
surface of cells undergoing apoptosis.
Puriﬁed CRP bound to a target can initiate and regulate
complement activation. CRP activates the classical
pathway (CP) and reduces alternative pathway (AP)
generation of the cell-lytic C5b-9 complex, and the protein
inhibits lectin pathway associated deposition of the C3b
opsonin (reviewed in Mold et al., 1999). Insofar as is
known CRP’s complement activating effect relies on
binding to the protein C1q, and its inhibitory effect
depends on binding factor H. At least invitro, complement
activation by ligand-bound CRP: (1) promotes the CP
mediated deposition of C3b and C4b onto CRP/ligand
complexes, (2) mediates solubilization of antigenic
CRP/ligand complexes, and (3) supports subsequent
recognition of the complexes by complement receptors
on phagocytes (Volanakis, 1982a,b; Volanakis and
Narkates, 1983; Mold et al., 1996; 1999). Complement
activation by CRP reportedly does not support formation
of an effective C5-convertase (Berman et al., 1986).
Other studies have shown that puriﬁed human CRP
binds FcgR expressed by both human and mouse cells
(Marnell et al., 1995; Bharadwaj et al., 1999; Stein et al.,
2000; Mold et al., 2001). X-ray crystallography revealed
a cleft on each CRP subunit, directly opposite the ligand-
binding site, which presumably accommodates binding of
both C1q and FcgR (Agrawal and Volanakis, 1994;
Agrawal et al., 2001). Notwithstanding the good evidence
showing CRP/FcgR interaction, this remains a somewhat
controversial issue because a few investigators have
concluded that CRP is not bound by leukocyte FcgR at all
(for example Hundt et al., 2001). How might the single
promiscuous binding site differentiate between inter-
actions with C1q versus FcgR, and how might the
seemingly disparate in vitro ﬁndings be resolved? The
answers remain equivocal but both questions are actively
being pursued by our group; we believe the recent
discovery that human CRP sometimes exists as a
glycoprotein (Das et al., 2003) might offer a potential
resolution. Brieﬂy, Mandal’s group showed that acute
phase CRP isolated from patients with inﬂammatory
conditions, including systemic lupus erythematosus
(SLE), was glycosylated. This was unexpected because
human CRP had previously been thought to be
unglycosylated. Glycosylation of CRP is a post-transla-
tional event and importantly, carbohydrate attaches to the
ﬂoor of the protein’s C1q/FcgR binding cleft (Das et al.,
2003). Based on the known effect that glycosylation has
on the ability of immunoglobulins to bind FcgR (Jefferis
and Lund, 2002) and to activate complement (Wright and
Morrison, 1997), we therefore predict that the C1q and
FcgR binding capacities of CRP are controlled by its
glycosylation state. If further study conﬁrms this
conjecture, this might explain some of the seemingly
paradoxical FcgR-binding results.
ADMINISTERED AND TRANSGENIC HUMAN
CRP PROTECTS LUPUS-PRONE MICE
Regardless of the exact nature of the interaction, it is
reasonable to suppose that CRP binding to apoptotic cells,
coupled with its ability to recruit complement and FcgR
mediated effector pathways, could modify the disease
phenotype in autoimmunity. In fact already there is strong
clinical and experimental evidence implicating involve-
ment of CRP in the pathogenesis of SLE. In most diseases
the blood level of CRP accurately reﬂects the degree of
underlying inﬂammation and tissue necrosis (Ballou and
Kushner, 1992), yet in SLE patients there is often little or
no increase in CRP (Pereira et al., 1980; Pepys et al.,
1982; Gabay et al., 1993). As already mentioned, CRP
binds to autoantigens of relevance in SLE (Robey et al.,
1985; Du Clos et al., 1988; Du Clos, 1989; Minota et al.,
1993; Gershov et al., 2000), and ligand-complexed CRP
can recruit the complement system and Fcg receptors in
both mouse and man. Thus via deposition of complement
cleavage fragments on both CRP and on the ligand
(Volanakis, 1982c; Volanakis and Narkates, 1983) CRP
can mediate complement-dependant solubilization of
chromatin (Robey et al., 1985) and likely assists in the
clearance of nuclear material from the circulation by
recruiting complement and FcgR. Early evidence that this
actually occurs in vivo is the detection of CRP in immune
complexes puriﬁed from sera of SLE patients, and reports
that human CRP administered to mice effects plasma
clearance of nucleosome core-particles and chromatin (Du
Clos et al., 1994; Burlingame et al., 1996).
Among mice the NZB/NZW hybrid strain (i.e. BW
mice) most accurately reﬂects the disease process
involved in human SLE; they display a pathognomonic
anti-nuclear autoantibody response that includes anti-
double stranded DNA (dsDNA) and they spontaneously
develop fulminate autoimmune glomerulonephritis (Theo-
ﬁlopoulos and Dixon, 1989). Also like humans the disease
is most frequent in females, susceptibility is inﬂuenced by
the MHC (mouse H-2), and non-H-2 loci are linked to the
organ-speciﬁc symptoms (Theoﬁlopoulos and Dixon,
1989; Vyse and Kotzin, 1998). Like the aberrant
expression of CRP in SLE patients, BW mice have
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1998). This is noteworthy as like CRP, SAP binds
chromatin and certain SAP
2/2 mice spontaneously
develop autoimmune nephritis (Bickerstaff et al., 1999).
Injected human CRP had been shown to offer some
protection against lupus in BW mice immunized with
chromatin (Du Clos et al., 1994), but other than a reported
transient decrease in anti-DNA and anti-histone antibodies
after the initial injection of chromatin, infused CRP did
not affect the autoimmune response and the beneﬁcial
effect was short-lived. The transient nature of the CRP
protective effect was attributed to the development of an
anti-CRP response in mice receiving human CRP.
Using a human transgene Ru ¨ther made CRP transgenic
mice (CRPtg) (Ciliberto et al., 1987) that express human
CRP as an acute phase protein and achieve blood levels of
CRP comparable to those in humans. We have since
generated many modiﬁed variants of Ru ¨ther’s original
CRPtg, and have used these to extensively study CRP’s
biological properties in vivo. Importantly, in CRPtg
generation of anti-human CRP is not a concern (Klein
et al., 1998). We recently showed that lupus-prone BW
mice carrying the CRP transgene had reduced proteinuria
and lived longer than non-transgenic BW (Szalai et al.,
2003). They also had lower IgM and higher IgG anti-
dsDNA titers than BW, accumulation of IgM and IgG in
the renal glomeruli was delayed, reduced, and more
mesangial than in BW, and end-stage accumulation of
IgG, IgM, and C3 in the renal cortex was prevented. Like
in some SLE patients, with disease progression in
CRPtg/BW there was little rise in plasma CRP; however,
to our surprise the protein became increasingly apparent in
the kidneys due to local expression of the transgene.
Our observation that IgM anti-dsDNA is lowered in
CRPtg/BW mice is consistent with a model recently
proposed to explain the autoimmunity preventing proper-
ties of SAP (Bickerstaff et al., 1999). Accordingly, CRP
might be preventing activation of autoreactive B cells by
promoting clearance of autoantigens (i.e. those displayed
by apoptotic cells) to non-antigen presenting sites in the
liver, and/or CRP may target delivery of autoantigens to
the bone marrow where autoreactive B cells are then
deleted or anergized. These possibilities have not yet been
investigated.
TRANSGENIC HUMAN CRP IS PROTECTIVE IN A
MOUSE MODEL OF MULTIPLE SCLEROSIS
Like lupus, we showed that CRPtg mice resist
experimental autoimmune encephalomyelitis (EAE), an
animal model of multiple sclerosis (MS) (Szalai et al.,
2002). In CRPtg compared to wildtype, the duration of the
human CRP acute phase response accompanying the
inductive phase of EAE correlated with a delay in disease
onset. In fact, there was little or no inﬁltration of the spinal
cord by CD3
þ and CD11b
þ inﬂammatory cells and EAE
was sometimes prevented altogether. CRPtg also resisted
EAE induced passively via transfer of encephalitogenic T
cells from symptomatic wildtype donors. Human CRP had
three effects on cultured encephalitogenic cells that likely
contributes to the protective effect we observed: (1) CRP
inhibited encephalitogenic peptide-induced proliferation
of T cells; (2) CRP inhibited production of inﬂammatory
cytokines and chemokines (TNF-a, INF-g, MIP-1a,
RANTES, MCP-1); and (3) CRP increased IL-10
production. Unlike in CRPtg/BW all three of these actions
were realized only in the presence of high concentrations
of human CRP. Ongoing studies have revealed that CRP
still mediates resistance to EAE in CRPtg that lack a
functional complement system, but CRPtg lacking certain
FcgR are not protected at all. In their entirety these data
suggest that during the acute-phase of inﬂammation in
CRPtg with EAE, the high level of circulating human CRP
achieved acts (in)directly on an FcgR-expressing cell(s)
and thus inhibits the damaging action of inﬂammatory
cells and/or T cells that otherwise support onset and
development of EAE.
CRPtg MICE RESIST EXPERIMENTALLY-
INDUCED APOPTOSIS
Lethal apoptosis can predictably be caused in mice by
injection of TNF-a or certain agonistic anti-Fas
antibodies (Xu et al., 2003), and it had been shown that
infusions of human CRP can protect mice against TNF-a-
induced hepatotoxicity (Van Molle et al., 1999; Mee-Ree
et al., 2000). We therefore investigated whether CRPtg
resist lethal experimentally-induced apoptosis. In the ﬁrst
instance mice received i.v. 1 £ 107 to 1 £ 109 plaque-
forming-units (pfu) of an adenovirus (Ad) vector that
expresses TNF-related apoptosis-inducing ligand
(TRAIL) receptor type 2 (R2) upon exposure to
tetracycline (Ichikawa et al., 2001). We found that in
CRPtg the serum level of mouse SAP and human CRP
FIGURE 1 CRPtg mice resist lethal apoptosis. On day -3 wildtype and
littermate CRPtg mice (10 mice pergroup) received i.v. 1 £ 10
7 pfu (low
dose) or 1 £ 10
9 pfu (high dose) of adenovirus vector engineered to
express TRAIL-R2 upon exposure to tetracycline (see accompanying
text). Expression of TRAIL-R2 induces fulminant apoptosis. At both
doses tested, CRPtg had improved survival.
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expression of Ad/TRAIL (data not shown), a ﬁnding
consistent with net depletion of SAP and CRP coincident
with induction of apoptosis. Presumably, this depletion is
due to participation of SAP and CRP in clearance of
apoptotic bodies. CRPtg ultimately had improved
survival (Fig. 1). In the second instance, systemic
apoptosis was induced in mice by infusion of the anti-
Fas antibody Jo2. Mice were injected intravenously with
0.344mg Jo2/g body weight, and then blood was collected
hourly. After 4h the major organs of mice were removed
and ﬁxed in buffered formalin. These were embedded in
parafﬁn and tissue sections were cut and processed to
enumerate the number of cells undergoing apoptosis
(TUNEL staining). In the spleens of Jo2-injected CRPtg
(Fig. 2C) the number of apoptotic cells was reduced
substantially compared to spleens from wildtype mice
(Fig. 2A). In the columnar epithelium of the intestine, Jo2
induced substantially more apoptosis but this too was
greatly reduced in CRPtg (compare Fig. 2, panels D
and B). Both observations are preliminary, but they are in
agreement with the expectation that CRP contributes to
clearance of apoptotic cells.
CRP-MEDIATED PROTECTION AGAINST
AUTOIMMUNITY: A HYPOTHESIS




to believe that CRP has the capacity to protect people with
autoimmunedisease.Attheveryleast,CRP’santimicrobial
properties (Szalai et al., 1995; 2000) should protect
rheumatic patients from deleterious infection. We propose
that the type and strength of CRP-mediated protection
againstautoimmunediseasevariesacrossaspectrumdueto
changes in the concentration and glycosylation state of
circulating CRP (Fig. 3). This likely determines the exact
nature and strength of CRP interaction with apoptotic and
FIGURE 2 Apoptosis induced by infusion of anti-Fas mAb Jo2 is reduced in CRPtg. Spleens and intestines were collected from wildtype C57BL/6
mice (A and B) and congenic CRPtg (C and D) 4h after injection of 0.344mg/g Jo2. TUNEL staining was performed to visualize apoptotic cells (brown
spots).
FIGURE 3 Hypothesized relationship between the concentration and
glycosylation state of circulating CRP and complement and FcgR
mediated clearance of apoptotic cells in autoimmune disease. See
accompanying text for details.
A.J. SZALAI 224effectorcells.Underbaselineconditionsperhapsinconcert
with complement, CRP could maintain a non-autoimmune
state by promoting the “silent” disposal of apoptotic cells.
During inﬂammation perhaps in concert with FcgR,
glycosylated CRP could support immune clearance of
opsonized targets by monocytes, which secrete IL-10 and
dampen inﬂammation.
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